Gene therapy approaches to ventricular tachyarrhythmias.
Ventricular tachycardia arising from a healed myocardial infarction scar continues to be a significant cause of morbidity and mortality. Drug therapy has been inadequate to meet this challenge, and implantable devices are limited by expense and technical problems. We have proposed the use of gene therapy for cardiac arrhythmias. In this review, we present a model of postinfarct ventricular tachycardia, a method for gene delivery to this area, and results of KCNH2-G628S gene transfer to manipulate cellular refractory properties in the arrhythmia model.
Donahue
J Kevin
JK
Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, Cleveland, OH, USA. kdonahue@metrohealth.org
Sasano
Tetsuo
T
Kelemen
Kamilla
K
D000818:Animals; D004195:Disease Models, Animal; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels / Q000235:genetics* / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D013552:Swine; D017180:Tachycardia, Ventricular / Q000235:genetics* / Q000628:therapy*; D016896:Treatment Outcome
D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; C000606913:KCNH2 protein, human